With the growing acceptance of the value of multi-parametric MRI (mpMRI) the detection, diagnosis and treatment of prostate cancer is undergoing a paradigm shift away from biomarkers and standard 12-core biopsies to imaging-based strategies with targeted biopsies.
In a 2015 Korean Journal of Urology review of mpMRI, the authors concluded that, “mpMRI, which is composed of T2WI and several functional sequences, is regarded as the single most accurate imaging modality for characterizing prostate cancer.” (published site)